CN1489580B - 咪唑衍生物 - Google Patents

咪唑衍生物 Download PDF

Info

Publication number
CN1489580B
CN1489580B CN028042557A CN02804255A CN1489580B CN 1489580 B CN1489580 B CN 1489580B CN 028042557 A CN028042557 A CN 028042557A CN 02804255 A CN02804255 A CN 02804255A CN 1489580 B CN1489580 B CN 1489580B
Authority
CN
China
Prior art keywords
methyl
imidazol
phenyl
methanol
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028042557A
Other languages
English (en)
Chinese (zh)
Other versions
CN1489580A (zh
Inventor
A·阿兰因
B·布特尔曼
M-P·海茨内德哈特
G·耶施克
E·皮纳德
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethiopia Wodtke International Co Ltd
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1489580A publication Critical patent/CN1489580A/zh
Application granted granted Critical
Publication of CN1489580B publication Critical patent/CN1489580B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN028042557A 2001-01-29 2002-01-21 咪唑衍生物 Expired - Fee Related CN1489580B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01101947.8 2001-01-29
EP01101947 2001-01-29
PCT/EP2002/000552 WO2002060877A1 (en) 2001-01-29 2002-01-21 Imidazole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101215002A Division CN101798298B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Publications (2)

Publication Number Publication Date
CN1489580A CN1489580A (zh) 2004-04-14
CN1489580B true CN1489580B (zh) 2010-05-26

Family

ID=8176317

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101215002A Expired - Fee Related CN101798298B (zh) 2001-01-29 2002-01-21 咪唑衍生物
CN028042557A Expired - Fee Related CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010101215002A Expired - Fee Related CN101798298B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Country Status (23)

Country Link
US (3) US6610723B2 (enExample)
EP (1) EP1358165B1 (enExample)
JP (1) JP4094956B2 (enExample)
KR (1) KR100619106B1 (enExample)
CN (2) CN101798298B (enExample)
AR (1) AR035422A1 (enExample)
AT (1) ATE425147T1 (enExample)
BR (1) BR0206758A (enExample)
CA (1) CA2434813C (enExample)
CY (1) CY1110265T1 (enExample)
DE (1) DE60231477D1 (enExample)
DK (1) DK1358165T3 (enExample)
ES (1) ES2319967T3 (enExample)
GC (1) GC0000318A (enExample)
GT (1) GT200200013A (enExample)
JO (1) JO2292B1 (enExample)
MX (1) MXPA03006773A (enExample)
MY (1) MY138334A (enExample)
PA (1) PA8537801A1 (enExample)
PE (1) PE20020917A1 (enExample)
PT (1) PT1358165E (enExample)
WO (1) WO2002060877A1 (enExample)
ZA (1) ZA200305626B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030144B2 (en) * 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
ITRM20050094A1 (it) * 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
WO2007042545A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
AU2008256926B2 (en) * 2007-05-23 2013-09-19 Allergan, Inc. ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
WO2010009327A1 (en) * 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112012018500A2 (pt) 2010-01-25 2016-08-16 Chdi Foundation Inc alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
WO2011101457A1 (en) 2010-02-18 2011-08-25 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2850508A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
JP2017520610A (ja) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション,インコーポレーテッド Hiv関連障害を治療するための方法及び組成物
DK3180315T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Pyrazoler
PL3180329T3 (pl) * 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazole jako inhibitory receptora NR2B
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
MA52244A (fr) 2018-04-04 2021-02-17 Janssen Pharmaceutica Nv Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
KR20220020915A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
PE20220806A1 (es) 2019-06-14 2022-05-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b
JP2022538774A (ja) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ.ベー. ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
KR20220020917A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN115656401B (zh) * 2022-11-09 2025-03-28 武汉海特生物创新医药研究有限公司 一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (de) 1986-08-11 1988-02-18 Schering Ag Imidazol-derivate
CN1040107C (zh) * 1993-01-02 1998-10-07 山道士有限公司 咪唑基甲基吡啶
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
EP1070708B1 (en) 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives

Also Published As

Publication number Publication date
MY138334A (en) 2009-05-29
MXPA03006773A (es) 2003-10-24
HK1146646A1 (en) 2011-06-24
EP1358165A1 (en) 2003-11-05
PA8537801A1 (es) 2002-09-17
US20020151715A1 (en) 2002-10-17
ES2319967T3 (es) 2009-05-18
CN101798298A (zh) 2010-08-11
US20030191311A1 (en) 2003-10-09
JO2292B1 (en) 2005-09-12
US6683097B2 (en) 2004-01-27
CY1110265T1 (el) 2015-01-14
GC0000318A (en) 2006-11-01
KR20030070615A (ko) 2003-08-30
JP4094956B2 (ja) 2008-06-04
ATE425147T1 (de) 2009-03-15
CA2434813A1 (en) 2002-08-08
CN1489580A (zh) 2004-04-14
US6610723B2 (en) 2003-08-26
US20030187268A1 (en) 2003-10-02
PT1358165E (pt) 2009-04-22
DE60231477D1 (en) 2009-04-23
CA2434813C (en) 2009-12-22
AR035422A1 (es) 2004-05-26
CN101798298B (zh) 2013-01-09
US6667335B2 (en) 2003-12-23
KR100619106B1 (ko) 2006-09-01
ZA200305626B (en) 2004-10-21
BR0206758A (pt) 2004-02-17
HK1063794A1 (en) 2005-01-14
GT200200013A (es) 2002-09-02
PE20020917A1 (es) 2002-10-19
JP2004523535A (ja) 2004-08-05
EP1358165B1 (en) 2009-03-11
DK1358165T3 (da) 2009-05-11
WO2002060877A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
CN1489580B (zh) 咪唑衍生物
JP3564133B2 (ja) ▲iv▼型ホスホジェステラーゼ阻害因子としてのキノリン類
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
EP1194144B1 (en) Antibacterial compounds
TWI452035B (zh) 以5員雜環為主之p38激酶抑制劑
US5332831A (en) Benzofuran derivatives
US5998437A (en) Benzimidazole derivatives
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
CZ303101B6 (cs) Prípravek podporující tvorbu/sekreci neurotropinu
JP2001064263A (ja) トリアゾール及びイミダゾール誘導体
US20080214622A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
US5922718A (en) Triazolones as apolipoprotein-B synthesis inhibitors
JP2003277379A (ja) 含窒素複素環化合物、その製造法および用途
US6248768B1 (en) Benzimidazole derivatives and pharmacologically acceptable salts thereof
AU2002246043B2 (en) Imidazole derivatives
HK1063794B (en) Imidazole derivatives
HK1146646B (en) Imidazole derivatives
AU2002246043A1 (en) Imidazole derivatives
TWI328584B (en) Imidazole derivatives
ME01934B (me) Derivati pirazola kao modulatori protein kinaze
JPWO2001030764A1 (ja) 1−置換フェニル−1−(1h−イミダゾール−4−イル)アルコール類、その製造法および用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1063794

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1063794

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: EVOTEC INTERNATIONAL GMBH

Free format text: FORMER OWNER: F. HOFFMANN-LA ROCHE AG

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: hamburg

Patentee after: Ethiopia wodtke International Co. Ltd.

Address before: Basel

Patentee before: F. Hoffmann-La Roche AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100526

Termination date: 20170121

CF01 Termination of patent right due to non-payment of annual fee